nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—CYP3A4—bone cancer	0.873	1	CbGaD
Repaglinide—SLCO1B1—Methotrexate—bone cancer	0.0199	0.58	CbGbCtD
Repaglinide—ALB—Methotrexate—bone cancer	0.0109	0.318	CbGbCtD
Repaglinide—CYP3A4—Doxorubicin—bone cancer	0.00353	0.103	CbGbCtD
Repaglinide—PPARG—periosteum—bone cancer	0.00313	0.215	CbGeAlD
Repaglinide—PPARG—leg—bone cancer	0.0025	0.172	CbGeAlD
Repaglinide—PPARG—forelimb—bone cancer	0.00248	0.17	CbGeAlD
Repaglinide—PPARG—hindlimb—bone cancer	0.00223	0.153	CbGeAlD
Repaglinide—PPARG—appendage—bone cancer	0.00191	0.132	CbGeAlD
Repaglinide—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.0017	0.0623	CbGpPWpGaD
Repaglinide—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00159	0.0584	CbGpPWpGaD
Repaglinide—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00116	0.0426	CbGpPWpGaD
Repaglinide—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	0.00108	0.0398	CbGpPWpGaD
Repaglinide—PPARG—Nuclear Receptors—NR1I2—bone cancer	0.00106	0.039	CbGpPWpGaD
Repaglinide—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00097	0.0357	CbGpPWpGaD
Repaglinide—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000927	0.0341	CbGpPWpGaD
Repaglinide—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000927	0.0341	CbGpPWpGaD
Repaglinide—Haemolytic anaemia—Cisplatin—bone cancer	0.000911	0.0179	CcSEcCtD
Repaglinide—Cardiac failure congestive—Cisplatin—bone cancer	0.000907	0.0178	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Cisplatin—bone cancer	0.000849	0.0167	CcSEcCtD
Repaglinide—PPARG—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000837	0.0308	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—FOLR1—bone cancer	0.00077	0.0283	CbGpPWpGaD
Repaglinide—Pancreatitis—Cisplatin—bone cancer	0.000697	0.0137	CcSEcCtD
Repaglinide—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000676	0.0249	CbGpPWpGaD
Repaglinide—Cardiovascular disorder—Epirubicin—bone cancer	0.000662	0.013	CcSEcCtD
Repaglinide—Hepatic enzyme increased—Methotrexate—bone cancer	0.000657	0.0129	CcSEcCtD
Repaglinide—Vasculitis—Methotrexate—bone cancer	0.000637	0.0125	CcSEcCtD
Repaglinide—Acute coronary syndrome—Cisplatin—bone cancer	0.000625	0.0123	CcSEcCtD
Repaglinide—Myocardial infarction—Cisplatin—bone cancer	0.000621	0.0122	CcSEcCtD
Repaglinide—Cardiovascular disorder—Doxorubicin—bone cancer	0.000612	0.012	CcSEcCtD
Repaglinide—Hepatobiliary disease—Cisplatin—bone cancer	0.000599	0.0118	CcSEcCtD
Repaglinide—Visual impairment—Cisplatin—bone cancer	0.000548	0.0108	CcSEcCtD
Repaglinide—PPARG—connective tissue—bone cancer	0.000546	0.0375	CbGeAlD
Repaglinide—ABCC8—Regulation of insulin secretion—GNA11—bone cancer	0.000541	0.0199	CbGpPWpGaD
Repaglinide—KCNJ11—tendon—bone cancer	0.000534	0.0367	CbGeAlD
Repaglinide—PPARG—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000532	0.0196	CbGpPWpGaD
Repaglinide—Eye disorder—Cisplatin—bone cancer	0.000532	0.0105	CcSEcCtD
Repaglinide—Cardiac disorder—Cisplatin—bone cancer	0.000528	0.0104	CcSEcCtD
Repaglinide—KCNJ11—Regulation of insulin secretion—GNA11—bone cancer	0.000525	0.0193	CbGpPWpGaD
Repaglinide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000521	0.0191	CbGpPWpGaD
Repaglinide—Immune system disorder—Cisplatin—bone cancer	0.000514	0.0101	CcSEcCtD
Repaglinide—Arrhythmia—Cisplatin—bone cancer	0.000508	0.00999	CcSEcCtD
Repaglinide—Alopecia—Cisplatin—bone cancer	0.000503	0.00989	CcSEcCtD
Repaglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000497	0.0183	CbGpPWpGaD
Repaglinide—Erythema—Cisplatin—bone cancer	0.000495	0.00974	CcSEcCtD
Repaglinide—Malnutrition—Cisplatin—bone cancer	0.000495	0.00974	CcSEcCtD
Repaglinide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00049	0.018	CbGpPWpGaD
Repaglinide—Hepatic function abnormal—Epirubicin—bone cancer	0.000483	0.0095	CcSEcCtD
Repaglinide—Visual disturbance—Methotrexate—bone cancer	0.000476	0.00936	CcSEcCtD
Repaglinide—ABCC8—spinal cord—bone cancer	0.000474	0.0326	CbGeAlD
Repaglinide—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000468	0.0172	CbGpPWpGaD
Repaglinide—Anaphylactoid reaction—Methotrexate—bone cancer	0.000466	0.00917	CcSEcCtD
Repaglinide—Cardiac failure congestive—Epirubicin—bone cancer	0.000466	0.00916	CcSEcCtD
Repaglinide—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.00045	0.0166	CbGpPWpGaD
Repaglinide—Hepatic function abnormal—Doxorubicin—bone cancer	0.000447	0.00879	CcSEcCtD
Repaglinide—Leukopenia—Cisplatin—bone cancer	0.000443	0.00872	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Epirubicin—bone cancer	0.000436	0.00858	CcSEcCtD
Repaglinide—Hypoglycaemia—Epirubicin—bone cancer	0.000433	0.00851	CcSEcCtD
Repaglinide—Cardiac failure congestive—Doxorubicin—bone cancer	0.000431	0.00847	CcSEcCtD
Repaglinide—PPARG—Generic Transcription Pathway—ZNF77—bone cancer	0.000427	0.0157	CbGpPWpGaD
Repaglinide—ABCC8—Integration of energy metabolism—GNA11—bone cancer	0.000426	0.0157	CbGpPWpGaD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000419	0.00823	CcSEcCtD
Repaglinide—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000417	0.0154	CbGpPWpGaD
Repaglinide—KCNJ11—Integration of energy metabolism—GNA11—bone cancer	0.000413	0.0152	CbGpPWpGaD
Repaglinide—Anaphylactic shock—Cisplatin—bone cancer	0.000404	0.00795	CcSEcCtD
Repaglinide—Oedema—Cisplatin—bone cancer	0.000404	0.00795	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000404	0.00794	CcSEcCtD
Repaglinide—Hypoglycaemia—Doxorubicin—bone cancer	0.0004	0.00787	CcSEcCtD
Repaglinide—Thrombocytopenia—Cisplatin—bone cancer	0.000396	0.00778	CcSEcCtD
Repaglinide—Skin disorder—Cisplatin—bone cancer	0.000392	0.00772	CcSEcCtD
Repaglinide—Pancreatitis—Methotrexate—bone cancer	0.000382	0.00752	CcSEcCtD
Repaglinide—PPARG—tendon—bone cancer	0.000375	0.0258	CbGeAlD
Repaglinide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000368	0.00724	CcSEcCtD
Repaglinide—PPARG—bone marrow—bone cancer	0.000364	0.025	CbGeAlD
Repaglinide—Paraesthesia—Cisplatin—bone cancer	0.000363	0.00714	CcSEcCtD
Repaglinide—Pancreatitis—Epirubicin—bone cancer	0.000358	0.00704	CcSEcCtD
Repaglinide—Angina pectoris—Epirubicin—bone cancer	0.000355	0.00699	CcSEcCtD
Repaglinide—Bronchitis—Epirubicin—bone cancer	0.000351	0.0069	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000349	0.00686	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000345	0.00678	CcSEcCtD
Repaglinide—Pancreatitis—Doxorubicin—bone cancer	0.000331	0.00651	CcSEcCtD
Repaglinide—Hyperglycaemia—Epirubicin—bone cancer	0.000329	0.00647	CcSEcCtD
Repaglinide—Angina pectoris—Doxorubicin—bone cancer	0.000329	0.00647	CcSEcCtD
Repaglinide—Hepatobiliary disease—Methotrexate—bone cancer	0.000329	0.00647	CcSEcCtD
Repaglinide—Bronchitis—Doxorubicin—bone cancer	0.000325	0.00639	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000323	0.00634	CcSEcCtD
Repaglinide—Jaundice—Epirubicin—bone cancer	0.000317	0.00624	CcSEcCtD
Repaglinide—Urinary tract infection—Epirubicin—bone cancer	0.000316	0.00622	CcSEcCtD
Repaglinide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000316	0.0116	CbGpPWpGaD
Repaglinide—Hepatitis—Methotrexate—bone cancer	0.000312	0.00614	CcSEcCtD
Repaglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000308	0.0113	CbGpPWpGaD
Repaglinide—Hepatobiliary disease—Epirubicin—bone cancer	0.000308	0.00605	CcSEcCtD
Repaglinide—Sinusitis—Epirubicin—bone cancer	0.000305	0.006	CcSEcCtD
Repaglinide—Hyperglycaemia—Doxorubicin—bone cancer	0.000305	0.00599	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—bone cancer	0.000301	0.00592	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000298	0.00587	CcSEcCtD
Repaglinide—Hypersensitivity—Cisplatin—bone cancer	0.000298	0.00586	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—bone cancer	0.000295	0.0058	CcSEcCtD
Repaglinide—Jaundice—Doxorubicin—bone cancer	0.000293	0.00577	CcSEcCtD
Repaglinide—Rhinitis—Epirubicin—bone cancer	0.000293	0.00576	CcSEcCtD
Repaglinide—Urinary tract infection—Doxorubicin—bone cancer	0.000293	0.00576	CcSEcCtD
Repaglinide—Hepatitis—Epirubicin—bone cancer	0.000292	0.00574	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—bone cancer	0.000292	0.00574	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—bone cancer	0.00029	0.0057	CcSEcCtD
Repaglinide—Oedema peripheral—Epirubicin—bone cancer	0.000288	0.00566	CcSEcCtD
Repaglinide—Hepatobiliary disease—Doxorubicin—bone cancer	0.000285	0.0056	CcSEcCtD
Repaglinide—Sinusitis—Doxorubicin—bone cancer	0.000282	0.00556	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—bone cancer	0.000282	0.00554	CcSEcCtD
Repaglinide—Visual impairment—Epirubicin—bone cancer	0.000281	0.00554	CcSEcCtD
Repaglinide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000281	0.0103	CbGpPWpGaD
Repaglinide—Diarrhoea—Cisplatin—bone cancer	0.000276	0.00544	CcSEcCtD
Repaglinide—Erythema multiforme—Epirubicin—bone cancer	0.000276	0.00543	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—bone cancer	0.000276	0.00542	CcSEcCtD
Repaglinide—Eye disorder—Epirubicin—bone cancer	0.000273	0.00537	CcSEcCtD
Repaglinide—Erythema—Methotrexate—bone cancer	0.000272	0.00534	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—bone cancer	0.000272	0.00534	CcSEcCtD
Repaglinide—Cardiac disorder—Epirubicin—bone cancer	0.000271	0.00533	CcSEcCtD
Repaglinide—Rhinitis—Doxorubicin—bone cancer	0.000271	0.00533	CcSEcCtD
Repaglinide—Hepatitis—Doxorubicin—bone cancer	0.00027	0.00532	CcSEcCtD
Repaglinide—Oedema peripheral—Doxorubicin—bone cancer	0.000266	0.00524	CcSEcCtD
Repaglinide—Immune system disorder—Epirubicin—bone cancer	0.000264	0.00519	CcSEcCtD
Repaglinide—Back pain—Methotrexate—bone cancer	0.000263	0.00517	CcSEcCtD
Repaglinide—Arrhythmia—Epirubicin—bone cancer	0.000261	0.00513	CcSEcCtD
Repaglinide—Visual impairment—Doxorubicin—bone cancer	0.00026	0.00512	CcSEcCtD
Repaglinide—Alopecia—Epirubicin—bone cancer	0.000258	0.00508	CcSEcCtD
Repaglinide—Vomiting—Cisplatin—bone cancer	0.000257	0.00505	CcSEcCtD
Repaglinide—Erythema multiforme—Doxorubicin—bone cancer	0.000256	0.00503	CcSEcCtD
Repaglinide—Rash—Cisplatin—bone cancer	0.000255	0.00501	CcSEcCtD
Repaglinide—Dermatitis—Cisplatin—bone cancer	0.000255	0.00501	CcSEcCtD
Repaglinide—Malnutrition—Epirubicin—bone cancer	0.000254	0.005	CcSEcCtD
Repaglinide—Erythema—Epirubicin—bone cancer	0.000254	0.005	CcSEcCtD
Repaglinide—Eye disorder—Doxorubicin—bone cancer	0.000253	0.00497	CcSEcCtD
Repaglinide—Cardiac disorder—Doxorubicin—bone cancer	0.000251	0.00493	CcSEcCtD
Repaglinide—PPARG—Regulation of retinoblastoma protein—MET—bone cancer	0.000247	0.00907	CbGpPWpGaD
Repaglinide—PPARG—Regulation of retinoblastoma protein—CDK4—bone cancer	0.000247	0.00907	CbGpPWpGaD
Repaglinide—Back pain—Epirubicin—bone cancer	0.000246	0.00484	CcSEcCtD
Repaglinide—Immune system disorder—Doxorubicin—bone cancer	0.000244	0.0048	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—bone cancer	0.000243	0.00478	CcSEcCtD
Repaglinide—Arrhythmia—Doxorubicin—bone cancer	0.000241	0.00475	CcSEcCtD
Repaglinide—Nausea—Cisplatin—bone cancer	0.00024	0.00472	CcSEcCtD
Repaglinide—Alopecia—Doxorubicin—bone cancer	0.000239	0.0047	CcSEcCtD
Repaglinide—Malnutrition—Doxorubicin—bone cancer	0.000235	0.00463	CcSEcCtD
Repaglinide—Erythema—Doxorubicin—bone cancer	0.000235	0.00463	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—bone cancer	0.000231	0.00455	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—bone cancer	0.000231	0.00455	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00023	0.00452	CcSEcCtD
Repaglinide—Leukopenia—Epirubicin—bone cancer	0.000228	0.00448	CcSEcCtD
Repaglinide—Back pain—Doxorubicin—bone cancer	0.000228	0.00448	CcSEcCtD
Repaglinide—Palpitations—Epirubicin—bone cancer	0.000225	0.00442	CcSEcCtD
Repaglinide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000224	0.00824	CbGpPWpGaD
Repaglinide—Anaphylactic shock—Methotrexate—bone cancer	0.000222	0.00436	CcSEcCtD
Repaglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—bone cancer	0.00022	0.0081	CbGpPWpGaD
Repaglinide—Hypertension—Epirubicin—bone cancer	0.00022	0.00432	CcSEcCtD
Repaglinide—PPARG—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	0.000218	0.00802	CbGpPWpGaD
Repaglinide—Thrombocytopenia—Methotrexate—bone cancer	0.000217	0.00427	CcSEcCtD
Repaglinide—Chest pain—Epirubicin—bone cancer	0.000216	0.00426	CcSEcCtD
Repaglinide—Arthralgia—Epirubicin—bone cancer	0.000216	0.00426	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—bone cancer	0.000215	0.00424	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000215	0.00423	CcSEcCtD
Repaglinide—PPARG—Regulation of retinoblastoma protein—RB1—bone cancer	0.000215	0.00789	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—DHFR—bone cancer	0.000211	0.00777	CbGpPWpGaD
Repaglinide—Leukopenia—Doxorubicin—bone cancer	0.000211	0.00414	CcSEcCtD
Repaglinide—Palpitations—Doxorubicin—bone cancer	0.000208	0.00409	CcSEcCtD
Repaglinide—Anaphylactic shock—Epirubicin—bone cancer	0.000208	0.00408	CcSEcCtD
Repaglinide—Oedema—Epirubicin—bone cancer	0.000208	0.00408	CcSEcCtD
Repaglinide—PPARG—Gene Expression—ZNF77—bone cancer	0.000206	0.00757	CbGpPWpGaD
Repaglinide—Thrombocytopenia—Epirubicin—bone cancer	0.000203	0.004	CcSEcCtD
Repaglinide—Hypertension—Doxorubicin—bone cancer	0.000203	0.004	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000202	0.00397	CcSEcCtD
Repaglinide—Skin disorder—Epirubicin—bone cancer	0.000202	0.00396	CcSEcCtD
Repaglinide—Chest pain—Doxorubicin—bone cancer	0.0002	0.00394	CcSEcCtD
Repaglinide—Arthralgia—Doxorubicin—bone cancer	0.0002	0.00394	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—bone cancer	0.000199	0.00392	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000199	0.00391	CcSEcCtD
Repaglinide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000199	0.0073	CbGpPWpGaD
Repaglinide—ABCC8—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000198	0.00728	CbGpPWpGaD
Repaglinide—Dyspepsia—Methotrexate—bone cancer	0.000195	0.00384	CcSEcCtD
Repaglinide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000194	0.00715	CbGpPWpGaD
Repaglinide—Anaphylactic shock—Doxorubicin—bone cancer	0.000192	0.00378	CcSEcCtD
Repaglinide—Oedema—Doxorubicin—bone cancer	0.000192	0.00378	CcSEcCtD
Repaglinide—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000192	0.00705	CbGpPWpGaD
Repaglinide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000191	0.00377	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000189	0.00372	CcSEcCtD
Repaglinide—Thrombocytopenia—Doxorubicin—bone cancer	0.000188	0.0037	CcSEcCtD
Repaglinide—Skin disorder—Doxorubicin—bone cancer	0.000186	0.00367	CcSEcCtD
Repaglinide—Paraesthesia—Epirubicin—bone cancer	0.000186	0.00367	CcSEcCtD
Repaglinide—ALB—Platelet degranulation—SPARC—bone cancer	0.000185	0.00681	CbGpPWpGaD
Repaglinide—PPARG—Regulation of retinoblastoma protein—MDM2—bone cancer	0.000183	0.00673	CbGpPWpGaD
Repaglinide—Dyspepsia—Epirubicin—bone cancer	0.000183	0.00359	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—bone cancer	0.000181	0.00357	CcSEcCtD
Repaglinide—PPARG—Circadian rythm related genes—GNA11—bone cancer	0.00018	0.00662	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—EZH2—bone cancer	0.000179	0.00659	CbGpPWpGaD
Repaglinide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000179	0.00352	CcSEcCtD
Repaglinide—Constipation—Epirubicin—bone cancer	0.000177	0.00349	CcSEcCtD
Repaglinide—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000176	0.00649	CbGpPWpGaD
Repaglinide—Urticaria—Methotrexate—bone cancer	0.000176	0.00346	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—bone cancer	0.000175	0.00345	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000175	0.00344	CcSEcCtD
Repaglinide—Paraesthesia—Doxorubicin—bone cancer	0.000172	0.00339	CcSEcCtD
Repaglinide—ABCC8—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000171	0.00628	CbGpPWpGaD
Repaglinide—Gastrointestinal pain—Epirubicin—bone cancer	0.00017	0.00334	CcSEcCtD
Repaglinide—Dyspepsia—Doxorubicin—bone cancer	0.000169	0.00332	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000166	0.00326	CcSEcCtD
Repaglinide—Urticaria—Epirubicin—bone cancer	0.000165	0.00324	CcSEcCtD
Repaglinide—Constipation—Doxorubicin—bone cancer	0.000164	0.00323	CcSEcCtD
Repaglinide—Abdominal pain—Epirubicin—bone cancer	0.000164	0.00323	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—bone cancer	0.000163	0.00321	CcSEcCtD
Repaglinide—PPARG—Regulation of retinoblastoma protein—JUN—bone cancer	0.000159	0.00585	CbGpPWpGaD
Repaglinide—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000158	0.00579	CbGpPWpGaD
Repaglinide—Gastrointestinal pain—Doxorubicin—bone cancer	0.000157	0.00309	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—bone cancer	0.000157	0.00309	CcSEcCtD
Repaglinide—ABCC8—Metabolism—NDUFA12—bone cancer	0.000155	0.00569	CbGpPWpGaD
Repaglinide—Hypersensitivity—Epirubicin—bone cancer	0.000153	0.00301	CcSEcCtD
Repaglinide—Urticaria—Doxorubicin—bone cancer	0.000153	0.003	CcSEcCtD
Repaglinide—Abdominal pain—Doxorubicin—bone cancer	0.000152	0.00299	CcSEcCtD
Repaglinide—Diarrhoea—Methotrexate—bone cancer	0.000152	0.00298	CcSEcCtD
Repaglinide—KCNJ11—Metabolism—NDUFA12—bone cancer	0.00015	0.00552	CbGpPWpGaD
Repaglinide—Pruritus—Epirubicin—bone cancer	0.000147	0.00289	CcSEcCtD
Repaglinide—PPARG—Generic Transcription Pathway—NR1I2—bone cancer	0.000145	0.00532	CbGpPWpGaD
Repaglinide—Diarrhoea—Epirubicin—bone cancer	0.000142	0.00279	CcSEcCtD
Repaglinide—Hypersensitivity—Doxorubicin—bone cancer	0.000141	0.00278	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—bone cancer	0.000141	0.00277	CcSEcCtD
Repaglinide—Rash—Methotrexate—bone cancer	0.00014	0.00275	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—bone cancer	0.00014	0.00275	CcSEcCtD
Repaglinide—Headache—Methotrexate—bone cancer	0.000139	0.00273	CcSEcCtD
Repaglinide—Pruritus—Doxorubicin—bone cancer	0.000136	0.00267	CcSEcCtD
Repaglinide—Vomiting—Epirubicin—bone cancer	0.000132	0.0026	CcSEcCtD
Repaglinide—Nausea—Methotrexate—bone cancer	0.000132	0.00259	CcSEcCtD
Repaglinide—Diarrhoea—Doxorubicin—bone cancer	0.000131	0.00258	CcSEcCtD
Repaglinide—Rash—Epirubicin—bone cancer	0.000131	0.00257	CcSEcCtD
Repaglinide—Dermatitis—Epirubicin—bone cancer	0.000131	0.00257	CcSEcCtD
Repaglinide—Headache—Epirubicin—bone cancer	0.00013	0.00256	CcSEcCtD
Repaglinide—ABCC8—Metabolism—NT5C3A—bone cancer	0.000128	0.00471	CbGpPWpGaD
Repaglinide—PPARG—Adipogenesis—RB1—bone cancer	0.000125	0.00459	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—NT5C3A—bone cancer	0.000124	0.00457	CbGpPWpGaD
Repaglinide—Nausea—Epirubicin—bone cancer	0.000123	0.00242	CcSEcCtD
Repaglinide—Vomiting—Doxorubicin—bone cancer	0.000122	0.0024	CcSEcCtD
Repaglinide—Rash—Doxorubicin—bone cancer	0.000121	0.00238	CcSEcCtD
Repaglinide—Dermatitis—Doxorubicin—bone cancer	0.000121	0.00238	CcSEcCtD
Repaglinide—Headache—Doxorubicin—bone cancer	0.00012	0.00237	CcSEcCtD
Repaglinide—Nausea—Doxorubicin—bone cancer	0.000114	0.00224	CcSEcCtD
Repaglinide—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000112	0.00411	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NDUFA12—bone cancer	0.000111	0.00408	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—CDK4—bone cancer	0.000101	0.00372	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—FUS—bone cancer	0.0001	0.00369	CbGpPWpGaD
Repaglinide—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	9.96e-05	0.00366	CbGpPWpGaD
Repaglinide—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.64e-05	0.00355	CbGpPWpGaD
Repaglinide—ABCC8—Neuronal System—BRAF—bone cancer	9.61e-05	0.00354	CbGpPWpGaD
Repaglinide—KCNJ11—Neuronal System—BRAF—bone cancer	9.32e-05	0.00343	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NT5C3A—bone cancer	9.19e-05	0.00338	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NDUFA12—bone cancer	8.73e-05	0.00321	CbGpPWpGaD
Repaglinide—CYP2C8—Biological oxidations—CYP3A4—bone cancer	8.37e-05	0.00308	CbGpPWpGaD
Repaglinide—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	8.25e-05	0.00304	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	8.21e-05	0.00302	CbGpPWpGaD
Repaglinide—ABCC8—Neuronal System—MDM2—bone cancer	8.05e-05	0.00296	CbGpPWpGaD
Repaglinide—KCNJ11—Neuronal System—MDM2—bone cancer	7.81e-05	0.00287	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	7.51e-05	0.00276	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NT5C3A—bone cancer	7.23e-05	0.00266	CbGpPWpGaD
Repaglinide—CYP2C8—Biological oxidations—GSTP1—bone cancer	7.16e-05	0.00263	CbGpPWpGaD
Repaglinide—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	7.06e-05	0.0026	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—NR1I2—bone cancer	6.96e-05	0.00256	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	6.81e-05	0.0025	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—JUN—bone cancer	6.52e-05	0.0024	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.38e-05	0.00235	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	6.3e-05	0.00232	CbGpPWpGaD
Repaglinide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.93e-05	0.00218	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—ENO2—bone cancer	5.61e-05	0.00207	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.51e-05	0.00203	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—ENO2—bone cancer	5.44e-05	0.002	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—DHFR—bone cancer	5.21e-05	0.00192	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—EIF2S1—bone cancer	5.14e-05	0.00189	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—DHFR—bone cancer	5.05e-05	0.00186	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NDUFA12—bone cancer	5.02e-05	0.00184	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NDUFA12—bone cancer	4.99e-05	0.00183	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—MET—bone cancer	4.93e-05	0.00181	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—CDK4—bone cancer	4.93e-05	0.00181	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—GNA11—bone cancer	4.87e-05	0.00179	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—TP53—bone cancer	4.72e-05	0.00174	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—GNA11—bone cancer	4.72e-05	0.00174	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—EZH2—bone cancer	4.47e-05	0.00164	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—CYP3A4—bone cancer	4.41e-05	0.00162	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—TP53—bone cancer	4.31e-05	0.00158	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—CYP3A4—bone cancer	4.28e-05	0.00157	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SPARC—bone cancer	4.23e-05	0.00156	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NT5C3A—bone cancer	4.16e-05	0.00153	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NT5C3A—bone cancer	4.13e-05	0.00152	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—MMP2—bone cancer	4.11e-05	0.00151	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—ENO2—bone cancer	4.02e-05	0.00148	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—GNA11—bone cancer	3.87e-05	0.00142	CbGpPWpGaD
Repaglinide—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.84e-05	0.00141	CbGpPWpGaD
Repaglinide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.79e-05	0.00139	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—GSTP1—bone cancer	3.77e-05	0.00139	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—DHFR—bone cancer	3.73e-05	0.00137	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—GSTP1—bone cancer	3.66e-05	0.00135	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IL3—bone cancer	3.51e-05	0.00129	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—GNA11—bone cancer	3.49e-05	0.00128	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ENO2—bone cancer	3.17e-05	0.00117	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—CYP3A4—bone cancer	3.16e-05	0.00116	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.15e-05	0.00116	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—MMP9—bone cancer	3.09e-05	0.00114	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—DHFR—bone cancer	2.94e-05	0.00108	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GNA11—bone cancer	2.75e-05	0.00101	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—GSTP1—bone cancer	2.7e-05	0.000995	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NDUFA12—bone cancer	2.69e-05	0.00099	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—EGFR—bone cancer	2.5e-05	0.000919	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CYP3A4—bone cancer	2.49e-05	0.000916	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.48e-05	0.000911	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PLAU—bone cancer	2.3e-05	0.000847	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NT5C3A—bone cancer	2.23e-05	0.000821	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GSTP1—bone cancer	2.13e-05	0.000783	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PTGS2—bone cancer	1.96e-05	0.000719	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PTGS2—bone cancer	1.9e-05	0.000697	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ENO2—bone cancer	1.82e-05	0.00067	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ENO2—bone cancer	1.81e-05	0.000666	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—DHFR—bone cancer	1.69e-05	0.000621	CbGpPWpGaD
Repaglinide—ALB—Metabolism—DHFR—bone cancer	1.68e-05	0.000618	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GNA11—bone cancer	1.58e-05	0.000581	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GNA11—bone cancer	1.57e-05	0.000577	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP3A4—bone cancer	1.43e-05	0.000526	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.42e-05	0.000524	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP3A4—bone cancer	1.42e-05	0.000523	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.42e-05	0.000521	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PTGS2—bone cancer	1.4e-05	0.000515	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTP1—bone cancer	1.22e-05	0.00045	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTP1—bone cancer	1.22e-05	0.000448	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PTGS2—bone cancer	1.1e-05	0.000406	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ENO2—bone cancer	9.77e-06	0.000359	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TP53—bone cancer	9.26e-06	0.00034	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—DHFR—bone cancer	9.07e-06	0.000333	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GNA11—bone cancer	8.47e-06	0.000312	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTP1—bone cancer	6.57e-06	0.000242	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTGS2—bone cancer	6.34e-06	0.000233	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTGS2—bone cancer	6.3e-06	0.000232	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTGS2—bone cancer	3.4e-06	0.000125	CbGpPWpGaD
